“Durlaza is an aspirin formulation for secondary prevention in high-risk CVD patients. The aspirin delivery technology in Durlaza extends the release of aspirin in a manner designed to provide a stable antiplatelet effect over the course of the day. The latter unique property of Durlaza is important as patients at risk generate new platelets throughout the day. Also, as one dosage form of any medication rarely works for all patients, Durlaza provides an alternative dosing option for patients who need aspirin for cardiovascular risk prevention,” said Paul Gurbel, MD, Associate Chief for Research and Director of the Sinai Center for Thrombosis Research, Sinai Hospital in Baltimore, MD, and Professor of Medicine, Johns Hopkins University.

Durlaza is expected to launch in the 4th quarter of 2015 and will be supplied as 162.5mg capsules in 30-count and 90-count bottles.

For more information call (203) 488-4620 or visit NewHavenPharma.com.


Continue Reading